# Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur

Source: https://onco.cc/trials/nct03836352/  
OnCo record `nct03836352` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cyclophosphamide, Pembrolizumab in ovarian cancer and hepatocellular carcinoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), active and no longer recruiting.

## Summary

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors is a phase 2 interventional study registered as NCT03836352 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 184 participants planned, started 2018-12-21 and due to reach its primary completion in 2023-12-31. Interventions recorded: DPX-Survivac, Cyclophosphamide, Pembrolizumab. Conditions listed: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03836352
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
- Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Enrolled: 184

## Sources

- ClinicalTrials.gov NCT03836352: https://clinicaltrials.gov/study/NCT03836352

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct03836352.json